These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 33386788)

  • 1. Social restriction versus herd immunity policies in the early phase of the SARS-CoV-2 pandemic: A mathematical modelling study.
    Chancharoenthana W; Leelahavanichkul A; Chinpraditsuk S; Pongpirul K; Kamolratanakul S; Phumratanaprapin W; Wilairatana P; Pitisuttithum P
    Asian Pac J Allergy Immunol; 2023 Sep; 41(3):253-262. PubMed ID: 33386788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toward Achieving a Vaccine-Derived Herd Immunity Threshold for COVID-19 in the U.S.
    Gumel AB; Iboi EA; Ngonghala CN; Ngwa GA
    Front Public Health; 2021; 9():709369. PubMed ID: 34368071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of vaccination on the COVID-19 pandemic in U.S. states.
    Chen X; Huang H; Ju J; Sun R; Zhang J
    Sci Rep; 2022 Jan; 12(1):1554. PubMed ID: 35091640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Creating and applying SIR modified compartmental model for calculation of COVID-19 lockdown efficiency.
    Sharov KS
    Chaos Solitons Fractals; 2020 Dec; 141():110295. PubMed ID: 32994671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What to Do in the Next Pandemic Outbreak: Natural Herd Immunity Versus Lockdown (Lessons Learned from COVID-19).
    Raposo VL
    J Law Med; 2022 Mar; 29(1):260-269. PubMed ID: 35362294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Travel-related control measures to contain the COVID-19 pandemic: a rapid review.
    Burns J; Movsisyan A; Stratil JM; Coenen M; Emmert-Fees KM; Geffert K; Hoffmann S; Horstick O; Laxy M; Pfadenhauer LM; von Philipsborn P; Sell K; Voss S; Rehfuess E
    Cochrane Database Syst Rev; 2020 Oct; 10():CD013717. PubMed ID: 33502002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID 19: Pandemic assessment and management using Incidence
    Braun P
    Int J Clin Pharmacol Ther; 2022 Jan; 60(1):1-4. PubMed ID: 34854373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Model based estimation of the SARS-CoV-2 immunization level in austria and consequences for herd immunity effects.
    Bicher M; Rippinger C; Schneckenreither G; Weibrecht N; Urach C; Zechmeister M; Brunmeir D; Huf W; Popper N
    Sci Rep; 2022 Feb; 12(1):2872. PubMed ID: 35190590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in adaptation of fifteen European countries population to SARS-CoV-2 in March-May 2020: Can Taiwanese experience be adopted?
    Sharov KS
    J Formos Med Assoc; 2021 Jan; 120(1 Pt 3):679-687. PubMed ID: 32798031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modelling COVID-19 dynamics and potential for herd immunity by vaccination in Austria, Luxembourg and Sweden.
    Kemp F; Proverbio D; Aalto A; Mombaerts L; Fouquier d'Hérouël A; Husch A; Ley C; Gonçalves J; Skupin A; Magni S
    J Theor Biol; 2021 Dec; 530():110874. PubMed ID: 34425136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 Modeling Outcome versus Reality in Sweden.
    Carlsson M; Söderberg-Nauclér C
    Viruses; 2022 Aug; 14(8):. PubMed ID: 36016462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Public health policies and health-care workers' response to the COVID-19 pandemic, Thailand.
    Nittayasoot N; Suphanchaimat R; Namwat C; Dejburum P; Tangcharoensathien V
    Bull World Health Organ; 2021 Apr; 99(4):312-318. PubMed ID: 33953449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamics of SARS-CoV-2 with waning immunity in the UK population.
    Crellen T; Pi L; Davis EL; Pollington TM; Lucas TCD; Ayabina D; Borlase A; Toor J; Prem K; Medley GF; Klepac P; Déirdre Hollingsworth T
    Philos Trans R Soc Lond B Biol Sci; 2021 Jul; 376(1829):20200274. PubMed ID: 34053264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transmission dynamics reveal the impracticality of COVID-19 herd immunity strategies.
    Brett TS; Rohani P
    Proc Natl Acad Sci U S A; 2020 Oct; 117(41):25897-25903. PubMed ID: 32963094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 exit strategy during vaccine implementation: a balance between social distancing and herd immunity.
    Daher-Nashif S; Al-Anany R; Ali M; Erradi K; Farag E; Abdallah AM; Emara MM
    Arch Virol; 2022 Sep; 167(9):1773-1783. PubMed ID: 35723757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individual variation in susceptibility or exposure to SARS-CoV-2 lowers the herd immunity threshold.
    Gomes MGM; Ferreira MU; Corder RM; King JG; Souto-Maior C; Penha-Gonçalves C; Gonçalves G; Chikina M; Pegden W; Aguas R
    J Theor Biol; 2022 May; 540():111063. PubMed ID: 35189135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reaching Herd Immunity During the SARS-CoV-2 Pandemic: What School Nurses Need to Know.
    Barnby E; Reynolds M; Gordon J
    NASN Sch Nurse; 2022 Jan; 37(1):13-18. PubMed ID: 34836470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the effectiveness of the search and find method to suppress spread of SARS-CoV-2.
    Sugawara H
    Proc Jpn Acad Ser B Phys Biol Sci; 2021; 97(1):22-49. PubMed ID: 33431724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2.
    Britton T; Ball F; Trapman P
    Science; 2020 Aug; 369(6505):846-849. PubMed ID: 32576668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.